A carregar...
Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
Recent studies have indicated that afatinib is beneficial for patients with non‐small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, while the effectiveness of afatinib rechallenge has not been fully defined. Here, we report a long‐term survival case o...
Na minha lista:
| Publicado no: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons Australia, Ltd
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7396375/ https://ncbi.nlm.nih.gov/pubmed/32529804 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13532 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|